RMD

ResMed
D

RMD

Arincen97/100B

ResMed cash on hand 1993–2027

ResMed had 1.01B USD in cash and short-term investments on 30 September 2026, down 27.0% on a year before. At the end of fiscal year 2026 it had 1.47B USD.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Cash on hand

Growth

Fiscal yearPeriod endingCash on handGrowthTotal debtNet cash
Latest quarter30 Sept 20261.01B-26.96%610.58M400.16M
FY202630 Jun 20261.47B+21.48%825.92M643.32M
FY202530 Jun 20251.21B+407.40%851.81M357.64M
FY202430 Jun 2024238.36M+4.59%873.94M-635.57M
FY202330 Jun 2023227.89M-16.74%1.58B-1.35B
FY202230 Jun 2022273.71M-7.30%917.55M-643.84M
FY202130 Jun 2021295.28M-36.25%793.72M-498.44M
FY202030 Jun 2020463.16M+214.80%1.30B-836.11M
FY201930 Jun 2019147.13M-22.03%1.27B-1.12B
FY201830 Jun 2018188.70M-77.04%281.45M-92.75M
FY201730 Jun 2017821.94M+12.37%1.08B-256.68M
FY201630 Jun 2016731.43M+1.98%1.17B-441.34M
FY201530 Jun 2015717.25M-20.81%300.59M416.66M
FY201430 Jun 2014905.73M+3.39%300.79M604.94M
FY201330 Jun 2013876.05M+8.22%300.79M575.26M
FY201230 Jun 2012809.54M+10.10%250.84M558.71M
FY201130 Jun 2011735.27M+50.43%100.16M635.10M
FY201030 Jun 2010488.78M+17.59%121.69M367.09M
FY200930 Jun 2009415.65M+29.45%161.74M253.91M
FY200830 Jun 2008321.08M+15.60%137.65M183.42M
FY200730 Jun 2007277.74M+26.51%116.00M161.74M
FY200630 Jun 2006219.54M+54.41%121.08M98.46M
FY200530 Jun 2005142.19M+0.89%174.37M-32.18M
FY200430 Jun 2004140.93M+16.45%113.25M27.68M
FY200330 Jun 2003121.02M+30.36%113.25M7.77M
FY200230 Jun 200292.84M-9.65%123.25M-30.41M
FY200130 Jun 2001102.75M+367.84%150.00M-47.25M
FY200030 Jun 200021.96M+31.51%0.0021.96M
FY199930 Jun 199916.70M+7.74%0.0016.70M
FY199830 Jun 199815.50M+70.33%200.00K15.30M
FY199730 Jun 19979.10M+65.45%600.00K8.50M
FY199630 Jun 19965.50M+66.67%900.00K4.60M
FY199530 Jun 19953.30M-10.81%800.00K2.50M
FY199430 Jun 19943.70M+117.65%400.00K3.30M
FY199330 Jun 19931.70M—300.00K1.40M

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet

Common questions about ResMed's cash

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.